News & Events
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
Crinetics announces the U. S. FDA accepted its New Drug Application for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults.
READ MORECrinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
Crinetics to showcase pipeline advancements with neuroendocrine tumor candidates at the 2024 NANETS Annual Meeting.
READ MORECrinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported third quarter 2024 financial and provided a business update on clinical progress.
READ MORECrinetics Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new non-executive employees.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
